CervoMed(CRVO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
CervoMed
CRVO.US
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB.
1.951 T
CRVO.USMarket value -Rank by Market Cap -/-

Financial Score

27/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking291/396
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-71.42%E
    • Profit Margin-415.36%E
    • Gross Margin-1772.60%E
  • Growth ScoreE
    • Revenue YoY-38.81%E
    • Net Profit YoY-114.15%E
    • Total Assets YoY-37.38%E
    • Net Assets YoY-43.00%E
  • Cash ScoreD
    • Cash Flow Margin-24.08%D
    • OCF YoY-38.81%E
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreA
    • Gearing Ratio15.03%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Venus Medtech Clarifies Position on U.S. Patent Lawsuit and Market Disclosure Obligations

    Venus Medtech (Hangzhou), Inc. has clarified its position regarding a U.S. patent infringement lawsuit filed by its subsidiary Cardiovalve and joint venture MTH IP against Edwards Lifesciences. The company stated it is not aware of any information that requires disclosure under Hong Kong regulations to prevent a false market. Shareholders and potential investors are advised to exercise caution. The current analyst rating for Venus Medtech's stock (HK:2500) is Hold, with a price target of HK$3.50 and a market cap of HK$1.49B.

    Tip Ranks·
    US
    CRVO
    +3.99%
    Tip Ranks·
    US
    CRVO
    +3.99%

    CervoMed Showcases Pipeline Progress and Neflamapimod’s Promise in Brain Disorders

    CervoMed Inc. has showcased its pipeline progress in treating age-related brain disorders, focusing on its lead drug candidate, neflamapimod. This oral small molecule targets neuroinflammation and neurodegeneration. Upcoming milestones include a Phase 3 trial for dementia with Lewy bodies and Phase 2a data for frontotemporal dementia and recovery after ischemic stroke. Neflamapimod has received FDA Fast Track and Orphan Drug designations. As of September 30, 2025, the company reported $27.3 million in cash and equivalents.

    Reuters·
    US
    CRVO
    +3.99%
    Reuters·
    US
    CRVO
    +3.99%

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    In Tuesday's after-market session, Ventyx Biosciences (VTYX) saw a significant gain of 57.2%, reaching $15.8, with a market cap of $558 million. Other gainers included Mainz Biomed (MYNZ) up 5.92% to $1.43, and Denali Therapeutics (DNLI) up 4.82% to $18.04. Conversely, CervoMed (CRVO) fell 3.1% to $7.31, while Biofrontera (BFRI) decreased by 3.04% to $0.77. Overall, the session highlighted notable movements in health care stocks, with both gains and losses across various companies.

    benzinga_article·
    US
    CRVO
    +3.99%
    US
    DNLI
    +3.11%
    US
    BFRI
    -1.80%
    benzinga_article·
    US
    CRVO
    +3.99%
    US
    DNLI
    +3.11%
    US
    BFRI
    -1.80%

    CervoMed Inc. Files Initial Statement of Beneficial Ownership for Director David Quigley

    CervoMed Inc. has filed a Form 3 with the SEC, naming David Quigley as a director. This filing is for informational purposes and not financial advice.

    Reuters·
    US
    CRVO
    +3.99%
    Reuters·
    US
    CRVO
    +3.99%

    CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital

    D. Boral Capital reaffirmed a "buy" rating for CervoMed with a $31.00 price target, indicating a potential upside of 236.23%. Other analysts have mixed ratings, with Zacks Research downgrading to "strong sell" and HC Wainwright upgrading to "buy". The stock opened at $9.22, with a market cap of $85.31 million. Insiders and hedge funds have been actively purchasing shares, with insiders owning 35.40% of the company.

    Market Beat·
    US
    CRVO
    +3.99%
    Market Beat·
    US
    CRVO
    +3.99%
    © 2026 Longbridge｜Disclaimer